Iron bioaccumulation in mycelium of Pleurotus ostreatus.

Pleurotus ostreatus is able to bioaccumulate several metals in its cell structures; however, there are no reports on its capacity to bioaccumulate iron. The objective of this study was to evaluate cultivation variables to increase iron bioaccumulation in P. ostreatus mycelium. A full factorial design and a central composite design were utilized to evaluate the effect of the following variables: nitrogen and carbon sources, pH and iron concentration in the solid culture medium to produce iron bioaccumulated in mycelial biomass. The maximum production of P. ostreatus mycelial biomass was obtained with yeast extract at 2.96 g of nitrogen L (-1) and glucose at 28.45 g L (-1) . The most important variable to bioaccumulation was the iron concentration in the cultivation medium. Iron concentration at 175 mg L (-1) or higher in the culture medium strongly inhibits the mycelial growth. The highest iron concentration in the mycelium was 3500 mg kg (-1) produced with iron addition of 300 mg L (-1) . The highest iron bioaccumulation in the mycelium was obtained in culture medium with 150 mg L (-1) of iron. Iron bioaccumulation in P. ostreatus mycelium is a potential alternative to produce non-animal food sources of iron.

Iron bioaccumulation in mycelium of Pleurotus ostreatus

Pleurotus ostreatus is able to bioaccumulate several metals in its cell structures; however, there are no reports on its capacity to bioaccumulate iron. The objective of this study was to evaluate cultivation variables to increase iron bioaccumulation in P. ostreatus mycelium. A full factorial design and a central composite design were utilized to evaluate the effect of the following variables: nitrogen and carbon sources, pH and iron concentration in the solid culture medium to produce iron bioaccumulated in mycelial biomass. The maximum production of P. ostreatus mycelial biomass was obtained with yeast extract at 2.96 g of nitrogen L−1 and glucose at 28.45 g L−1. The most important variable to bioaccumulation was the iron concentration in the cultivation medium. Iron concentration at 175 mg L−1 or higher in the culture medium strongly inhibits the mycelial growth. The highest iron concentration in the mycelium was 3500 mg kg−1 produced with iron addition of 300 mg L−1. The highest iron bioaccumulation in the mycelium was obtained in culture medium with 150 mg L−1 of iron. Iron bioaccumulation in P. ostreatus mycelium is a potential alternative to produce non-animal food sources of iron.

Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.

BACKGROUND: Glatiramer acetate is a US FDA category B drug with regard to use by pregnant women with multiple sclerosis (MS). There are no data currently available for the continuous use of glatiramer acetate during pregnancy. OBJECTIVE: To assess the risks and benefits of glatiramer acetate used throughout pregnancy among women with active MS. DESIGN: Retrospective and multicentre case series. SETTINGS: Outpatient services of academic and private institutions caring for patients with MS in Brazil. PATIENTS: Eleven women with MS and their children were assessed. INTERVENTION: Retrospective evaluation of women with MS who received glatiramer acetate continuously for at least 7 months during pregnancy. This evaluation was performed by the neurologist responsible for the patient. Children aged 1 year and over, born to mothers who received glatiramer acetate during pregnancy, were assessed using the Denver II developmental screening test. MAIN OUTCOME MEASUREMENTS: Obstetric, neonatal and developmental outcomes. RESULTS: No drug-related obstetric complications were observed. No specific drug-related malformations, neonatal complications or developmental abnormalities were observed in the children. Postnatal MS relapse rates remained significantly lower than antenatal rates in these patients. CONCLUSIONS: No deleterious effects from glatiramer acetate were observed in these pregnant women with MS or in their offspring. No increment in postnatal relapse rate was observed. However, the use of glatiramer acetate during pregnancy should be restricted to the most difficult cases, in which the benefits clearly outweigh the risks.

Carcinoma adenóide cístico da mama / Adenoid cystic carcinoma of the breast

Carcinoma adenóide cístico da mama é uma neoplasia rara. Tem seu curso biológico com progressão lenta e ausência de metástases para linfonodos axilares. Ao contrário do carcinoma adenóide cístico extramamário, o prognóstico do carcinoma adenóide cístico da mama é excelente. É importante diferençar esse tipo de câncer de outros tipos de neoplasias da mama pelo excelente prognóstico.

Adenoid cystic carcinoma of the breast is a rare neoplasm. It has a biological course of slow progression and near absence of axillary lymph node metastasis. In contrast to extramammary adenoid cystic carcinoma, the prognosis of adenoid cystic carcinoma of the breast is excellent. It is important to distinguish this cancer from other forms of breast cancer because of its excellent prognosis.